Connection

Robert Stuart to Naphthyridines

This is a "connection" page, showing publications Robert Stuart has written about Naphthyridines.
Connection Strength

1.200
  1. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2015 Mar; 168(6):796-805.
    View in: PubMed
    Score: 0.482
  2. Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs. 2012 Aug; 21(8):1223-33.
    View in: PubMed
    Score: 0.408
  3. Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.
    View in: PubMed
    Score: 0.154
  4. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
    View in: PubMed
    Score: 0.126
  5. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2015 Feb; 100(2):231-7.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.